Everolimus (Afinitor) Approved for Advanced Unresectable or Metastatic Pancreatic Neuroendocrine Tumors (PNET)

On May 5, 2011, the FDA approved everolimus (Afinitor) for treatment of advanced unresectable or metastatic progressive neuroendocrine tumors of pancreatic origin.   

The approval was based on a randomized comparison of everolimus at 10 mg orally/day versus placebo.  The median progression-free survival (PFS) was 11.0 versus 4.6 months, respectively (p<0.001).  This respresents a major advance for patients with this aggressive form of cancer, for which there were few treatment options.

Tags: , , , ,

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s


%d bloggers like this: